Company Description
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally.
The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery.
The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults.
It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications.
The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors.
Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
| Country | United States |
| Founded | 1944 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 712 |
| CEO | David A. Battat |
Contact Details
Address: One Allentown Parkway Allen, Texas 75002 United States | |
| Phone | (972) 390-9800 |
| Website | atrioncorp.com |
Stock Details
| Ticker Symbol | ATRI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000701288 |
| CUSIP Number | 049904105 |
| ISIN Number | US0499041053 |
| Employer ID | 63-0821819 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Emile A. Battat | Executive Chairman |
| David A. Battat | President and Chief Executive Officer |
| Cindy Ferguson | Vice President, Chief Financial Officer, Secretary and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | ARS | Filing |
| Apr 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |